Skip to content
Try Mental Wellness – Lifestyle
Author:
Kyowa Kirin
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
June 10, 2026
FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
May 14, 2026
CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program
May 6, 2026